S.C. Medical Oncology, Azienda Ospedaliera S. Maria, Terni, Italy.
Division of Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy.
Crit Rev Oncol Hematol. 2019 Jul;139:149-157. doi: 10.1016/j.critrevonc.2018.07.009. Epub 2018 Aug 1.
In the so-called "antiangiogenic era" of recent years, a number of targeted therapies have been approved for the treatment of metastatic renal cell carcinoma (mRCC). Emerging information about the immunological features of mRCC and the immunomodulating properties of antiangiogenic agents, one of the standard treatments for mRCC, indicates that a more rational design of potentially synergistic combinations should be pursued. Indeed, immunotherapy has undergone a resurgence in clinical practice. In this narrative review, we discuss the immunological features of mRCC and the potential interactions that antiangiogenic agents may also exert on host immunity and tumor immunogenicity, possibly working on both sides of this complex cross-talk. Hence, the recall to Gianus, the ancient two-faced Roman God who was looking both at the future and the past. Treatment strategies will be also critically discussed.
在近年来所谓的“抗血管生成时代”，许多针对转移性肾细胞癌（mRCC）的靶向治疗药物已获得批准。mRCC 的免疫特征和抗血管生成药物（mRCC 的标准治疗方法之一）的免疫调节特性方面的新信息表明，应寻求更合理的潜在协同组合的设计。事实上，免疫疗法在临床实践中重新兴起。在本叙述性综述中，我们讨论了 mRCC 的免疫学特征，以及抗血管生成药物可能对宿主免疫和肿瘤免疫原性产生的潜在相互作用，这些作用可能同时作用于这一复杂串扰的正反两面。因此，这让人想起了古希腊两面神雅努斯，他既能看到未来，也能看到过去。还将对治疗策略进行批判性讨论。
